NCT05569928View on ClinicalTrials.gov

In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects

NAUnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

January 30, 2025

Conditions
Familial HypobetalipoproteinemiaFamilial Hypobetalipoproteinemia - Heterozygous Form
Interventions
OTHER

Administration of deuterated compounds for kinetic study

Participants will be submitted to a standardized oral-fat load and kinetic study will be performed

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Göteborg University

OTHER

collaborator

University of Helsinki

OTHER

lead

Marcello Arca

OTHER

NCT05569928 - In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects | Biotech Hunter | Biotech Hunter